In normal plasma, the serine protease inhibitor a,-antitrypsin (al-AT) plays little or no role in the control of plasma kallikrein or activated Factor XII fragment (Factor XIIf), this function being performed by Cl-inhibitor. Recently, an al-AT variant was described with a Met -Arg mutation at the reactive center PI residue (position 358) which altered the specificity of inhibition from the Met-or Val-specific protease neutrophil elastase to thrombin, an Arg-specific protease. We have now examined the inhibition of plasma kallikrein and Factor XIIf, both Arg-specific enzymes, with recombinant a1-AT(Mete--p Arg) produced by an Escherichia coli strain carrying a mutated human a,-AT gene.
Introduction a,-Antitrypsin (a,-AT)' belongs to a family of serine protease inhibitors that includes antithrombin III, a2-antiplasmin, and Cl-inhibitor (1) . These molecules possess a single and inhibitorspecific reactive site peptide bond that is formed between adjacent amino acid residues termed PI and P. (1) . The reactivity ofthese inhibitors with proteolytic enzymes depends heavily upon the nature of the residue at position PI, the central position of the reactive center (1) . For example, when the PI Met of a,-AT is replaced by Arg, the resulting a1-AT(Met358 X Arg) or a,-AT (Pittsburgh) efficiently inhibits thrombin, but loses the neutrophil elastase-inactivating capacity of normal a,-AT (2) . Moreover, a recent report indicates that natural a1-AT(Met358 -Arg) is efficient in inhibiting other Arg-specific proteases, including plasma kallikrein and activated Factor XII fragment (Factor XIIf) (3).
1. Abbreviations used in this paper: a,-AT, a1-antitrypsin; Factor XIIf, Factor XII fragment; r, recombinant; SDS-PAGE, sodium dodecyl sulfatepolyacrylamide gel electrophoresis. a,-AT complementary DNA has already been cloned and expressed in Escherichia coli (4) . Furthermore, site-directed mutagenesis ofthe cloned a,-AT cDNA has allowed the synthesis of recombinant (r) a,-AT variants with specific mutations at the P1 residue, such as the Pittsburgh mutant analogue ra,-AT(Met358 a Arg) and the oxidation-resistant variant ral-AT(Met358 Val) (5) . In the present report, we have examined the reactivity of ra,-AT and two variant forms with plasma kallikrein and Factor XIIf.
Methods
Proteins. Plasma kallikrein (6) and Factor XIIf (7) were prepared as indicated. ra1-AT, ral-AT(Met358 -Arg), and ral-AT(Met358 -Val) were purified using standard techniques (manuscript in preparation) from the E. coli strains previously described (5 Under these conditions, the hydrolysis rate of S-2302 was 82 pmol/min with I mg kallikrein (8) and 17.8,umol/min with I mg Factor XIIf (7) . Pseudo-first-order (k') and second-order (k") rate constants for the reaction between kallikrein or Factor XIIf and the various ra1-AT species were determined according to Kitz and Wilson (9) .
Electrophoretic studies. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (10) was performed using vertical slab gels. The concentration of acrylamide in the separating gel was 10%. Nonreducing conditions were used.
Results
The inactivation of kallikrein amidolytic activity by various concentrations of ral-AT, ral-AT(Met358 -Arg), and ral-AT(Met358 -Val) followed pseudo-first-order kinetics when these inhibitors were in a 7-380-fold molar excess (Fig. 1) . ral-AT(Met358 -Arg) was dramatically more efficient in inactivating kallikrein than was ral-AT or ral-AT(Met358 -Val). with an inhibitor concentration of 0.57 juM (Fig. 2, triangles) , while k" was 2.13 X 106 M-I min-' (Fig. 2, inset) (Fig. 3, lane c) , no such complex was formed using ral-AT under the same conditions (Fig. 3 , lane e). A similar observation was made with Factor XIIf, which formed a complex with an apparent Mr of70,000 when incubated for min with ra,-AT(Met358 Arg) (Fig. 3, lane g ), but not when incubated for 10 min with ral-AT (Fig. 3, lane h ).
Discussion
The results presented here demonstrate that ral-AT(Met358 Arg) is a very efficient inhibitor of both plasma kallikrein and Factor XIIf. Kinetically, the second-order rate constant, ki, for the reaction between kallikrein and this inhibitor, was 17,000 times greater than the k" calculated for the reaction with natural a,-AT (11), ra1-AT, or ral-AT(Met358 -Val) (Fig. 1) . In addition, a k" value of 2.13 X 106 M-min' was found for the reaction between ral-AT(Met358 -Arg) and Factor XIIf. Since this serine protease did not react at a detectable rate with natural a,-AT (7), ral-AT, or ral-AT(Met358 -Val) (Fig. 2) , this observation emphasizes the critical role of Arg at the P1 position for the inactivation of Factor XIIf.
Plasma protease inhibitors of the a,-AT family react with their target enzymes to form stable and apparently covalent enzyme-inhibitor complexes (1) . When the products of the inactivation of kallikrein or Factor XIIf by ra1-AT(Met358 -Arg) were analyzed by SDS-PAGE, new species with Mr of 120,000 and 70,000 were formed (Fig. 3, lanes c and g) leads to the formation of 1:1 stoichiometric complexes. The predominant inhibitor in normal plasma of kallikrein and Factor XIIf is Cl-inhibitor (7, 12) . In purified systems, this inhibitor reacts with kallikrein and Factor XIIf with k' values of 1.02 and 0.19 X 106 M-' min-, respectively (7, 13) . Thus, on a molar basis, ral-AT(Met358 -Arg) was more efficient than Cl-inhibitor with both kallikrein (4.1 -fold) and Factor XIIf ( 11.5-fold). This suggests that ral-AT(Met358 -Arg) could be useful for the management of disease states associated with unregulated activation of prekallikrein and Factor XII, such as hereditary angioedema attacks, septic shock, and the adult respiratory distress syndrome (14) (15) (16) ). The only patient described with the a,-AT (Pittsburgh) variant died at age 14 after an intermittent but lifelong hemorrhagic diathesis (2, 17) . When the patient was bleeding, the plasma concentration ofa-AT(Met358 -Arg) was -40 ,M, which fell by a factor of 3.6 during the quiescent stage (2) 
